Asia Pacific Microcarriers Market Forecast to 2030 - Regional Analysis - by Product, Equipment, Application, and End User

The Asia Pacific microcarriers market is expected to grow from US$ 366.14 million in 2022 to US$ 991.23 million by 2030. It is estimated to record a CAGR of 13.3% from 2022 to 2030.

Surge in Adoption of Regenerative Medicine Fuels Asia Pacific Microcarriers Market

The rising adoption of regenerative medicine has emerged as a significant driver propelling the growth of the microcarriers market. Regenerative medicine focuses on repairing, replacing, or regenerating damaged tissues and organs, making it a promising field for addressing various medical conditions. Microcarriers play a pivotal role in the cultivation and expansion of cells, a fundamental aspect of regenerative medicine.

In regenerative medicine, cells are cultured outside the body before being transplanted, and microcarriers provide a suitable environment for cell attachment, proliferation, and differentiation. They serve as a substrate for cell growth in bioreactors, facilitating the efficient production of large quantities of cells. This is particularly crucial for regenerative therapies, where a substantial number of viable and functional cells are needed.

Moreover, microcarriers enhance the scalability and cost-effectiveness of cell processes, addressing key challenges in the translation of regenerative medicine from research to clinical applications. As the regenerative medicine field continues to advance, with an increasing focus on stem cell therapies and tissue engineering, the demand for microcarriers is expected to escalate, driving innovation and expansion within the microcarriers market

Asia Pacific Microcarriers Market Overview

The microcarrier market in Asia Pacific is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific countries. Several countries in Asia Pacific invest significantly in cell and gene therapy R&D. China, India, and Japan are the three major contributors to the growth of the microcarriers market in this region, and the market growth can be attributed to the growing emphasis of businesses on cost optimization, burgeoning efforts to streamline clinical processes, supportive government policies, and increasing number of clinical trials. The government of the People's Republic of China is focused on improving public health, providing cost-effective public health programs, expanding the coverage of health-related financial protection measures, and investing in a vast healthcare delivery network. The 13th Chinese plan expected a more than 4% contribution of the biotechnology industry to the GDP in 2020, which would be nearly 10-20 life-science parities. More than 100 life-science parks controlled by local governments are functional across China, and these centers entice enterprises with tax advantages and subsidies. State, provincial, and local governments are reported to have already invested more than US$ 100 billion in the biosciences sector to meet the goals of the five-year plan of China. In 2003, it became the first country to approve a gene therapy, and since then, the development of cell and gene therapies with elevated therapeutic potential has picked pace worldwide. According to a study published in Nature in 2021, China is home to more than 50% of all cell therapy trials across the world. The country currently has nearly 400 ongoing CAR-T trials centered on hematology, and oncology and solid tumors. In 2021, the National Medical Products Administration (NMPA) approved Fosun Kite's Yescarta and JW Therapeutics' Relma-cel, with which cell therapies in China entered a new era.

Asia Pacific Microcarriers Market Segmentation

The Asia Pacific microcarriers market is segmented into product, equipment, application, end user, and country.

Based on product, the Asia Pacific microcarriers market is bifurcated into microcarriers beads and media & reagents. The microcarriers beads segment held a larger share of the Asia Pacific microcarriers market in 2022.

In terms of equipment, the Asia Pacific microcarriers market is segmented into bioreactors, culture vessels, and others. The bioreactors segment held the largest share of the Asia Pacific microcarriers market in 2022.

Based on application, the Asia Pacific microcarriers market is segmented into biopharmaceutical production, cell and gene therapy, tissue engineering and regenerative medicine, and other. The biopharmaceutical production segment held the largest share of the Asia Pacific microcarriers market in 2022. Further, biopharmaceutical production segment is categorized into therapeutic protein production and vaccine production.

Based on end user, the Asia Pacific microcarriers market is segmented into pharmaceutical & biotechnology companies, contract research organizations & contract manufacturing organizations, and academic & research institutes. The pharmaceutical & biotechnology companies segment held the largest share of the Asia Pacific microcarriers market in 2022.

Based on country, the Asia Pacific microcarriers market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China dominated the Asia Pacific microcarriers market in 2022.

Teijin Ltd, Bio-Rad Laboratories Inc, Sartorius AG, Danaher Corp, Corning Inc, Eppendorf SE, Asahi Kasei Corp, and Polysciences Inc are some of the leading companies operating in the Asia Pacific microcarriers market.